Fidaxomicin: First-in-class macrocyclic antibiotic

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 7, 2011, Pages 767-777

  Mullane, Kathleen M ^a   Gorbach, Sherwood ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Optimer Pharmaceuticals Inc   (United States)

Author keywords

Clostridium difficile; difimicin; fidaxomicin; macrocyclic antibiotic; OPT 80; PAR 101

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; DRUG METABOLITE; FIDAXOMICIN; METRONIDAZOLE; OP 1118; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANEMIA; ANTIBACTERIAL ACTIVITY; ARTHRALGIA; BACKACHE; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BLOOD ANALYSIS; BLOOD TOXICITY; CHILL; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONNECTIVE TISSUE DISEASE; CONSTIPATION; COUGHING; CROSS RESISTANCE; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FECES LEVEL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DYSPEPSIA; DYSPNEA; EDEMA; FALLING; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HOSPITAL INFECTION; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INSOMNIA; INTESTINE FLORA; KIDNEY FUNCTION TEST; LIMB PAIN; LIVER FUNCTION TEST; LYMPHATIC SYSTEM DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIPLE DRUG DOSE; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; PNEUMONIA; POSTANTIBIOTIC EFFECT; QT PROLONGATION; RECURRENCE RISK; RECURRENT INFECTION; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; SEPSIS; SIDE EFFECT; THORAX DISEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; URINARY TRACT DISEASE; URINARY TRACT INFECTION; VOMITING;

ACTINOMYCETALES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLINICAL TRIALS, PHASE III AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DNA-DIRECTED RNA POLYMERASES; GASTROINTESTINAL TRACT; HUMANS; MICROBIAL SENSITIVITY TESTS; NUCLEIC ACID SYNTHESIS INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VANCOMYCIN;

EID: 79961203458     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.53     Document Type: Review

References (67)

1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N. Engl. J. Med. 330, 257-262 (1994). (Pubitemid 24034138)
2. Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. J. Infect. 61, 1-8 (2010).
3. McGowan AP, Lalayiannis LC, Sharma JB et al. Thirty-day mortality of Clostridium difficile infection in a UK National Health Service Foundation Trust between 2002 and 2008. J. Hosp. Infect. 77, 11-15 (2011).
4. Blanckaert K, Coignard B, Grandbastien B et al. Update on Clostridium difficile infections. Rev. Med. Interne. 29(3), 209-214 (2008). (Pubitemid 351625404)
5. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med. 346, 334-339 (2002).
6. Gerding DN, Olson MM, Peterson LR et al. Clostridium difficile-associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch. Intern. Med. 146, 95-100 (1986). (Pubitemid 16158635)
7. Marciniak C, Chen D, Stein AC, Semik PE. Prevalence of Clostridium difficile colonization at admission to rehabilitation. Arch. Phys. Med. Rehabil. 87, 1086-1090 (2006). (Pubitemid 44107839)
8. Riggs MM, Sethi AK, Zabarsky TF et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin. Infect. Dis. 45, 992-998 (2007). (Pubitemid 47580347)
9. Gerding DN. Global epidemiology of Clostridium difficile infection in 2010. Infect. Control Hosp. Epidemiol. 31(Suppl. 1), S32-S34 (2010).
10. Gould LH, Lumgago B. Clostridium difficile in food and domestic animals: a new foodborne pathogen? Clin. Infect. Dis. 51(5), 577-582 (2010).
11. Rupnik M. Clostridium difficile: (re) emergence of zoonotic potential. Clin. Infect. Dis. 51(5), 583-584 (2010).
12. Gerding DN. Disease associated with Clostridium difficile infection. Ann. Intern. Med. 110, 255-257 (1989). (Pubitemid 19062152)
13. McFarland LV, Stamm WE. Review of Clostridium difficile-associated diseases. Am. J. Infect. Control 14, 99-109 (1986). (Pubitemid 16088636)
14. Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect. Control Hosp. Epidemiol. 23, 653-659 (2002). (Pubitemid 35315987)
15. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA).Infect. Control Hosp. Epidemiol. 31(5), 431-455 (2010).
16. Roda PI. Clostridium difficile colitis induced by cytarabine. Am. J. Clin. Oncol. 10, 451-452 (1987). (Pubitemid 18070521)
17. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin. Infect. Dis. 17, 109-113 (1993). (Pubitemid 23197574)
18. Kim KH, Fekety R, Batts DH et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J. Infect. Dis. 143, 42-50 (1981). (Pubitemid 11152596)
19. Collins MD, Lawson PA, Willems A et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int. J. Syst. Bacteriol. 44, 812-826 (1994). (Pubitemid 24315163)
20. Tannock GW, Munro K, Taylor C et al. A new macrocycle antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156, 11, 3354-3359 (2010).
21. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442-2449 (2005). (Pubitemid 41770165)
22. Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26, 273-280 (2005). (Pubitemid 40445086)
23. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433-2441 (2005). (Pubitemid 41770164)
24. Pearson A. Historical and changing epidemiology of healthcare-associated infections. J. Hosp. Infect. 73, 296-304 (2009).
25. Warny M, Pepin J, Fang A et al. Toxin producton by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079-1084 (2005). (Pubitemid 41338761)
26. Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr. Opin. Gastroenterol. 23(1), 4-9 (2007). (Pubitemid 44875902)
27. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut 57, 850-860 (2008). (Pubitemid 351716982)
28. Spigaglia P, Mastriantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J. Clin. Microbiol. 40(9), 3470-3475 (2002). (Pubitemid 34977470)
29. CDC. Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb. Mortal. Wkly Rep. 54, 1201-1205 (2005).
30. Rouphael NG, O'Donnell JA, Bhatnagar J et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am. J. Obstet. Gynecol. 198(6), 635 e1-e6 (2008).
31. Maroo S, LaMont JT. Recurrent Clostridium difficile. Gastroenterology 130, 1311-1316 (2006).
32. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40, 1586-1590 (2005). (Pubitemid 40720807)
33. Pépin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40, 1591-1597 (2005). (Pubitemid 40720808)
34. Pépin J, Valiquette L, Gagnon S et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am. J. Gastroenterol. 102, 2781-2788 (2007). (Pubitemid 350179349)
35. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infec. Control Hosp. Epidemiol. 28(11), 1219-1227 (2007). (Pubitemid 47596558)
36. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34, 346-353 (2002). (Pubitemid 34062235)
37. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 30(1), 57-66 (2009).
38. Parenti F, Pagani H, Beretta G. Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. J. Antibiot. 28, 247-252 (1975).
39. Theriault RJ, Karwowski JP, Jackson M et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. J. Antibiot. 40, 567-574 (1987).
40. Gerber M, Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: a review. Expert. Opin. Investig. Drugs 17, 547-553 (2008). (Pubitemid 351578171)
41. Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr. Opin. Investig. Drugs 8, 168-173 (2007). (Pubitemid 46438471)
42. Swanson RN, Hardy DJ, Shipkowitz NL et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob. Agents Chemother. 35, 1108-1111 (1991).
43. Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob. Agents Chemother. 48, 2280-2282 (2004). (Pubitemid 38691631)
44. Sergio S, Pirali G, White R, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes; III. Mechanism of action. J. Antibiot. 38(7), 543-549 (1975).
45. Sears P, Babakhani F, Citron DM et al. Typing and susceptibility of bacterial isolates from the OPT-80 (PAR-101) Phase 2A study for C. difficile-associated diarrhea. Presented at: 9th Biennial Congress of the Anaerobe Society of the Americas, Long Beach, CA, USA, 24-27 June 2008 (Poster).
46. Seddon J, Sears P. Preliminary OPT-80 mode of action studies. Optimer Pharmaceuticals, Inc. Report Number BIO090203A (2003).
47. Osburne M, Sonenshein A. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis. J. Virol. 33, 945-953 (1980). (Pubitemid 10184105)
48. Sonenshein A, Alexander H, Rothstein D, Fisher S. Lipiarmycin resistant ribonucleic acid polymerase mutants of Bacillus subtilis. J. Bacteriol. 132, 73-79 (1977). (Pubitemid 8194521)
49. Coronelli C, White RJ, Lancini GC et al. A new antibiotic from Actinoplanes; II. Isolation, chemical, biological and biochemical characterization. J. Antibiot. 28(4), 253-259 (1975).
50. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48(11), 4430-4434 (2004). (Pubitemid 39434908)
51. Louie TJ, Emery J, Krulicki W et al. 2009 OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53, 261-262 (2009).
52. Babakhani F, Seddon, J, Robert N et al. Effect of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) vs. Clostridium difficile. Antimicrob. Agents Chemother. 54, 2674-2676 (2010).
53. Sears P, Louie TJ, Mullane KM et al. Pharmacokinetics/pharmacodynamics (PK/PD) of fidaxomicin in treatment of Clostridium difficile infection (CDI).Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).San Francisco, CA, USA, 12-15 September 2009.
54. Louie T, Miller M, Donskey C et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a Phase 2 trial with patients with Clostridium difficile infection. Antimicrob. Agents Chemother. 53(1), 223-228 (2009).
55. Okumu F, Walsh RB, Sears P, Shue YK. Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD).Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).Washington, DC, USA, 30 October-2 November 2004.
56. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422-431 (2011).
57. Crook D, Weiss K, Cornely OA et al. Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin. Programs and Abstracts of the 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria (2010) (Abstract LB 2401).
58. Nelson RL. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 3, CD004610 (2007).
59. Shue YK, Sears PS, Shangle S et al. Safety, tolerance and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob. Agents Chemother. 52, 1391-1395 (2008). (Pubitemid 351522003)
60. Gorbach S, Weiss K, Sears P, Pullman J. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection. Programs and Abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA (2009) (Abstract L1-1640).
61. Nerandzic MM, Mullane K, Miller M et al. Acquisiton and overgrowth of vancomycin-resistant enterococci in patients treated with fidaxomicin (FDX) versus vancomycin (VAN) for Clostridium difficile infection. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 12-15 September 2009.
62. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5(9), 549-557 (2005). (Pubitemid 41196754)
63. Louie TJ, Peppen J, Watt CK et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 43, 411-420 (2006). (Pubitemid 44157147)
64. Musher DM, Logan N, Hamill RJ. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 43, 421-427 (2006). (Pubitemid 44157148)
65. Louie T, Gerson M, Grimard D et al. Results of a Phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD).Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA, 17-20 September 2007 (Poster 3826).
66. Gerding D. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin. Infect. Dis. 25(Suppl. 2) S206-S210 (1997).
67. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 12(3), 409-415 (2006).